Globus Medical (GMED)

NYSE
Currency in USD
58.90
-1.30(-2.16%)
Closed·
After Hours
58.50-0.40(-0.68%)
·
GMED Scorecard
Full Analysis
High shareholder yield
GMED is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
58.7059.99
52 wk Range
54.4894.93
Key Statistics
Edit
Prev. Close
60.2
Open
59.64
Day's Range
58.7-59.99
52 wk Range
54.48-94.93
Volume
1.15M
Average Volume (3m)
1.46M
1-Year Change
-10.64%
Book Value / Share
29.72
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GMED Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
85.17
Upside
+44.60%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Globus Medical News & Analysis

Show more

Globus Medical Company Profile

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Globus Medical SWOT Analysis


Spine Market Leade
Globus Medical, an $8 billion spine and orthopedics powerhouse, faces challenges while pursuing strategic growth in robotics and emerging technologies
Financial Resilience
Despite Q1 2025 setbacks, Globus maintains 2025 guidance. Analysts project EPS of $3.10-$3.40, with an average price target of $100
Strategic Acquisitions
Explore Globus Medical's expansion into neuromodulation with Nevro Corp acquisition and the successful integration of NuVasive merge
Innovation Drive
Delve into Globus Medical's robust product pipeline, including 18 new launches in 2024 and record-breaking performance in Emerging Technology segment
Read full SWOT analysis

Globus Medical Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $0.68 missed $0.75 forecast; revenue of $598.1M below $631.09M expectation; stock dropped 17.9% after hours
  • Record Q1 free cash flow of $141.2M, up 493% YoY; repurchased 2.4M shares; paid off $450M convertible debt
  • Reaffirmed 2025 sales guidance of $2.8-2.9B; lowered non-GAAP EPS guidance to $3.0-3.3 from $3.1-3.4
  • Acquired Nevro for $250M; launched two new products; facing supply chain disruptions and elongated selling cycles
  • Management expects Q2 improvements in spine and enabling technologies; focused on Nevro integration and expense reduction
Last Updated: 08/05/2025, 22:32
Read Full Transcript

Compare GMED to Peers and Sector

Metrics to compare
GMED
Peers
Sector
Relationship
P/E Ratio
43.0x−13.2x−0.5x
PEG Ratio
0.300.160.00
Price/Book
2.0x3.0x2.6x
Price / LTM Sales
3.2x2.6x3.1x
Upside (Analyst Target)
31.2%59.2%50.4%
Fair Value Upside
Unlock−3.0%8.7%Unlock

Analyst Ratings

8 Buy
6 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 85.17
(+44.60% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
0.68 / 0.75
Revenue / Forecast
598.10M / 631.09M
EPS Revisions
Last 90 days

People Also Watch

42.92
G
-1.54%
53.46
KBR
-0.43%
296.33
WTW
-1.59%
42.65
RHI
-2.60%
206.18
AVB
-1.27%

FAQ

What Is the Globus Medical (GMED) Stock Price Today?

The Globus Medical stock price today is 58.90

What Stock Exchange Does Globus Medical Trade On?

Globus Medical is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Globus Medical?

The stock symbol for Globus Medical is "GMED."

What Is the Globus Medical Market Cap?

As of today, Globus Medical market cap is 7.97B.

What Is Globus Medical's Earnings Per Share (TTM)?

The Globus Medical EPS (TTM) is 1.36.

When Is the Next Globus Medical Earnings Date?

Globus Medical will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is GMED a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Globus Medical Stock Split?

Globus Medical has split 0 times.

How Many Employees Does Globus Medical Have?

Globus Medical has 5300 employees.

What is the current trading status of Globus Medical (GMED)?

As of 14 Jun 2025, Globus Medical (GMED) is trading at a price of 58.90, with a previous close of 60.20. The stock has fluctuated within a day range of 58.70 to 59.99, while its 52-week range spans from 54.48 to 94.93.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.